| Metric | Current | Prior | YoY |
|---|---|---|---|
| Revenue | ¥20.6B | ¥19.3B | +6.8% |
| Operating Income | ¥2.1B | ¥1.6B | +33.8% |
| Ordinary Income | ¥2.1B | ¥1.6B | +34.3% |
| Net Income | ¥1.4B | ¥0.9B | +45.6% |
| ROE | 4.1% | 2.8% | - |
FY2026 Q2 cumulative results (first half): Revenue ¥20.6B (YoY +6.8%), Operating Income ¥2.1B (+33.8%), Ordinary Income ¥2.1B (+34.3%), Net Income ¥1.4B (+45.6%). The company achieved revenue growth with significantly stronger profit expansion, driven by gross margin maintenance at 33.8% and controlled SG&A expenses at 23.7% of revenue. Operating margin improved to 10.2% from prior period levels. Basic EPS rose to ¥57.47 (+45.6% YoY), reflecting strong bottom-line performance. Operating cash flow reached ¥4.2B (+209.5% YoY), representing 3.11 times net income and confirming high-quality cash-backed earnings. Free cash flow of ¥1.6B was generated after CapEx of ¥2.6B. Financial position remains conservative with equity ratio of 74.1%, cash and deposits of ¥15.7B covering short-term debt of ¥1.2B by 13.1 times, and current ratio of 431%. Progress against full-year guidance appears on track with first-half revenue representing 46.8% and operating income 51.6% of annual targets.
Revenue increased ¥1.3B (+6.8%) YoY to ¥20.6B, driven by steady business expansion across operating segments. Cost of sales rose to ¥13.6B while maintaining gross profit margin at 33.8%, indicating stable pricing power and cost management. SG&A expenses of ¥4.9B remained controlled at 23.7% of revenue, contributing to operating leverage. The combination of revenue growth and expense discipline drove operating income up ¥0.5B (+33.8%) to ¥2.1B, with operating margin expanding approximately 1.9 percentage points to 10.2%. Non-operating items remained minimal with negligible interest income and expenses, resulting in ordinary income of ¥2.1B (+34.3%), closely aligned with operating profit. Extraordinary losses of ¥0.1B were recorded, primarily comprising impairment losses of ¥0.06B attributed to the Bio segment within "Other" operations, plus securities valuation losses of ¥0.1B. These non-recurring charges reduced profit before tax to ¥2.0B. After income tax expense of ¥0.7B (effective tax rate approximately 33.7%), net income reached ¥1.4B (+45.6%), with the amplified net income growth reflecting both operational improvement and lapping of prior period factors. The results represent a revenue up/profit up pattern, with profit growth significantly outpacing revenue expansion due to margin improvement and operational efficiency gains.
Segment-level operating profit data is not disclosed in the available information. The segment footnotes indicate three reporting segments exist: Reliability Assessment Business, Microfabrication Business, and Other (including Bio and Zero Innovation businesses), with corporate costs allocated separately. However, specific revenue and operating income figures by segment are not provided. Qualitative notes mention that impairment losses of ¥5.9M were recorded in the Other segment relating to Bio operations, suggesting this remains a developing business with profitability challenges.
[Profitability] ROE of 4.1% reflects moderate return on equity given the conservative capital structure, with net profit margin of 6.6% and operating margin of 10.2% showing improved profitability versus prior periods. The DuPont analysis indicates ROE is composed of net profit margin 6.6%, asset turnover 0.459, and financial leverage 1.35. Gross profit margin of 33.8% demonstrates solid product/service pricing power, while SG&A ratio of 23.7% leaves room for further operating leverage as revenue scales. [Cash Quality] Cash and deposits of ¥15.7B provide substantial liquidity, covering short-term debt of ¥1.2B by 13.1 times and representing 35.0% of total assets. Operating cash flow of ¥4.2B significantly exceeded net income, yielding an OCF/NI ratio of 3.11, confirming high earnings quality. [Investment Efficiency] Asset turnover of 0.459 indicates moderate capital efficiency, with total assets of ¥44.9B generating ¥20.6B in first-half revenue. CapEx of ¥2.6B exceeded depreciation of ¥2.2B by 1.17 times, indicating growth-oriented capital investment. Receivables turnover stands at approximately 118 days (DSO), suggesting extended collection cycles that warrant monitoring. Work-in-process inventory represents 90% of total inventory, reflecting the project-based or custom manufacturing nature of operations. [Financial Health] Equity ratio of 74.1% reflects a highly conservative balance sheet with equity of ¥33.2B against total assets of ¥44.9B. Current ratio of 431% demonstrates exceptional short-term liquidity with current assets of ¥26.2B versus current liabilities of ¥6.1B. Debt-to-equity ratio of 0.036 and net debt-to-EBITDA of 0.28 times indicate minimal leverage. Interest coverage is extremely strong given negligible interest expenses.
Operating cash flow of ¥4.2B represents 3.11 times net income, confirming strong cash conversion with operating CF subtotal before working capital changes of ¥4.6B including depreciation of ¥2.2B. Working capital movements showed inventory increase of ¥0.9B absorbing cash as work-in-process builds, partially offset by receivables decrease of ¥0.4B contributing positive cash impact, while payables remained essentially flat. Income taxes paid of ¥0.4B and minimal interest paid reflect the company's low-leverage profile. Investing cash flow of negative ¥2.6B was entirely driven by capital expenditures of ¥2.6B, representing continued investment in production and technological capabilities at 1.17 times depreciation, supporting future growth capacity. Financing cash flow of negative ¥1.3B primarily reflected dividend payments of ¥0.9B with no significant debt transactions. Free cash flow of ¥1.6B (operating CF minus CapEx) demonstrates the company's ability to fund both growth investment and shareholder returns from operating cash generation, with FCF coverage of 1.88 times the dividend payment indicating sustainable cash distribution capacity.
Ordinary income of ¥2.1B versus operating income of ¥2.1B shows minimal non-operating impact, with non-operating income and expenses both near zero, indicating core business operations drive substantially all profitability. Interest income and interest expense are both negligible at ¥0.0B, reflecting the company's net cash position and conservative financial management. Non-operating income represents less than 1% of revenue, consisting primarily of minor financial income items. Extraordinary losses of ¥0.1B comprising impairment losses of ¥0.06B in the Bio segment and securities valuation losses of ¥0.1B represent non-recurring charges totaling approximately 0.5% of revenue, having limited impact on underlying earnings power. Operating cash flow of ¥4.2B significantly exceeds net income of ¥1.4B, indicating healthy earnings quality with strong cash realization. The accruals ratio of negative 6.4% suggests conservative accounting with cash generation outpacing reported earnings. Cash conversion rate (OCF/EBITDA) of 0.98 confirms that nearly all operating profit converts to cash, further validating earnings quality.
Progress against full-year FY2026 guidance shows revenue of ¥20.6B representing 46.8% of the ¥44.0B target, operating income of ¥2.1B at 51.6% of the ¥4.0B target, ordinary income of ¥2.1B at 51.9% of the ¥4.0B target, and net income of ¥1.4B reaching 50.3% of the ¥2.7B target. All metrics track ahead of the standard 50% first-half benchmark, indicating solid progress. The company maintained its full-year guidance with no revisions this quarter, implying confidence in achieving annual targets. Revenue guidance implies second-half acceleration to ¥23.4B (YoY +11.5%) versus first-half ¥20.6B (+6.8%), suggesting expected seasonal strength or business momentum. Operating income guidance implies ¥2.0B in the second half versus ¥2.1B in the first half, potentially reflecting planned investment or conservative planning. Net income guidance of ¥2.7B (+23.4% YoY) for the full year indicates expected continued profit growth outpacing revenue expansion. Forecast notes indicate assumptions are based on currently available information and reasonable premises, with actual results subject to variation. The company plans an individual investor results briefing on February 20, 2026, with materials to be disclosed on TDnet and the company website.
Annual dividend forecast is ¥37.00 with no distribution in the interim period, representing a year-end single payment policy. Based on forecast EPS of ¥115.43, the dividend payout ratio is calculated at 32.1% of projected full-year earnings, representing a moderate and sustainable return policy. Against first-half actual EPS of ¥57.47, the annual dividend represents a 64.4% payout ratio, though this comparison is less meaningful given the year-end payment timing. Using full-year net income guidance of ¥2.7B and 2,350 thousand shares outstanding, total dividend payment would approximate ¥86.9M, well within free cash flow capacity of ¥1.6B generated in the first half alone. No share buyback program is disclosed. The total shareholder return ratio, consisting solely of dividends, stands at 32.1% based on full-year projections, leaving substantial retained earnings for growth investment and financial flexibility.
Working capital efficiency deterioration poses operational risk, with days sales outstanding of 118 days indicating extended receivable collection cycles and cash conversion cycle of 176 days reflecting capital tied up in operating assets. The work-in-process inventory ratio of 90% suggests concentration in project-based or custom manufacturing with inherent execution and timing risks. Failure to improve working capital turnover could constrain cash generation despite profit growth. Business diversification risk exists within the Other segment, where impairment losses of ¥5.9M were recorded in Bio operations, indicating development-stage businesses with uncertain profitability timelines. Continued investment without clear path to returns could pressure overall margins. Dividend sustainability requires monitoring given the calculated 64.4% payout ratio against first-half earnings, though this is mitigated by strong cash position of ¥15.7B and robust operating cash flow. Any unexpected profit deterioration or working capital absorption could pressure the ability to maintain the ¥37 dividend while funding growth CapEx of 1.17 times depreciation.
[Industry Position] (Reference - Proprietary Analysis)
The company operates in the IT/Telecom sector where FY2025 Q2 industry benchmarks provide comparative context. Profitability metrics show ROE of 4.1% underperforming the industry median of 5.6%, with net profit margin of 6.6% below the median of 9.2% and operating margin of 10.2% below the median of 14.0%, indicating room for improvement in converting revenue to profit relative to peers. Financial health demonstrates equity ratio of 74.1% exceeding the industry median of 60.2%, reflecting a more conservative capital structure than typical sector participants. The current ratio of 431% significantly surpasses the industry median of 7.74x, indicating exceptional liquidity positioning. Efficiency metrics reveal mixed performance: asset turnover of 0.459 exceeds the industry median of 0.35, demonstrating relatively stronger capital efficiency, while receivables turnover of 118 days compares to industry median of 117 days, suggesting in-line but not superior collection performance. Revenue growth of 6.8% YoY trails the industry median of 21.0%, positioning the company as a slower-growth participant within a generally expanding sector. The CapEx/D&A ratio of 1.17 substantially exceeds the industry median of 0.34, indicating more aggressive growth investment relative to asset base. Cash conversion ratio of 0.98 aligns with the industry median of 1.22, confirming solid cash realization. EPS growth of 45.6% significantly outpaces the industry median of 35.0%, reflecting superior bottom-line expansion despite modest top-line growth. The company's Rule of 40 score (revenue growth plus operating margin) of approximately 17% falls below the industry median of 31%, suggesting opportunity to improve the balance of growth and profitability.
※ Industry: IT/Telecom (7 companies), Comparison: Prior fiscal periods, Source: Proprietary analysis
Profit leverage significantly exceeds revenue growth with operating income expanding 33.8% and net income up 45.6% against revenue growth of 6.8%, driven by margin expansion from 8.3% to 10.2% operating margin and effective cost management. This demonstrates strong operational gearing as the business scales, though revenue growth trails the 21% industry median, suggesting market share or end-market factors may constrain top-line expansion. Cash generation quality is exceptional with operating cash flow of ¥4.2B representing 3.11 times net income and growing 209.5% YoY, substantially outpacing profit growth and confirming robust working capital management improvements in the period despite structural DSO and inventory challenges flagged in quality metrics. The combination of strong FCF of ¥1.6B and conservative balance sheet with 74.1% equity ratio and minimal debt provides substantial financial flexibility for continued growth investment at 1.17x depreciation and sustainable shareholder returns at 32% projected payout ratio. Structural working capital efficiency challenges require attention, with 118-day DSO, 176-day cash conversion cycle, and 90% work-in-process concentration indicating capital intensity in operations that if improved could unlock significant cash flow and return on invested capital expansion. The company's lower revenue growth relative to IT/Telecom peers (6.8% vs 21% median) combined with investment-stage losses in development businesses like Bio within the Other segment suggest portfolio optimization and focus on higher-return core operations could enhance overall returns toward or above the industry ROE median of 5.6% from current 4.1%.
This report was automatically generated by AI analyzing XBRL earnings data as an earnings analysis tool. This is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled from publicly available earnings data. Please make investment decisions at your own responsibility and consult professionals as needed.